Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

(2015) Nickolay Neznanov et al.   Oncotarget

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

(2010) G. Roue et al.   BLOOD

Development of target-specific treatments in multiple myeloma

(2010) Asher A. Chanan-Khan et al.   BRITISH JOURNAL OF HAEMATOLOGY

New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

(2010) T. Nakashima et al.   CLINICAL CANCER RESEARCH

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

(2010) J. J. Wright   CLINICAL CANCER RESEARCH

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

(2010) Alessandro Allegra et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

(2009) Sagar Lonial et al.   BRITISH JOURNAL OF HAEMATOLOGY

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aranorosin and a novel derivative inhibit the anti-apoptotic functions regulated by Bcl-2

(2008) Takayuki Nakashima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

(2008) H. Gu et al.   MOLECULAR CANCER THERAPEUTICS